Search research articles
Contact Us
Filters
Showing results (1-10 of 81) with videos related to
Page
of 9
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
February 1, 2022
Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS)
Onyee Chan, Najla Al Ali, David Sallman, et al.
Journal of Geriatric Oncology
|
July 16, 2020
Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis
Tea Reljic, Marina Sehovic, Jeffrey Lancet, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 11, 2017
Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome
Susmitha Apuri, Najla Al Ali, Eric Padron, et al.
Blood Advances
|
September 21, 2022
U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes
Rami Komrokji, Luis E Aguirre, Najla Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 14, 2016
Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome
Mintallah Haider, Najla Al Ali, Eric Padron, et al.
Blood Cancer Journal
|
November 15, 2022
Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
Andrew M Brunner, Alexander Gavralidis, Najla Al Ali, et al.
Blood
|
May 26, 2021
Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes
Rami Komrokji, Virginia Volpe, Onyee Chan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 23, 2015
Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome
Rami Komrokji, Hanadi Ramadan, Najla Al Ali, et al.
Haematologica
|
November 24, 2022
<i>IDH</i> mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy
Rami Komrokji, Najla Al Ali, Onyee Chan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 14, 2016
Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience
Joanna Grabska, Bijal Shah, Damon Reed, et al.
Page
of 9
Search research articles
Search
Showing results (1-10 of 81) with videos related to
Sort By:
Page
of 9
Clinical Lymphoma, Myeloma & Leukemia
|
February 1, 2022
Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS)
Onyee Chan, Najla Al Ali, David Sallman, et al.
Journal of Geriatric Oncology
|
July 16, 2020
Benchmarking treatment effects for patients over 70 with acute myeloid leukemia: A systematic review and meta-analysis
Tea Reljic, Marina Sehovic, Jeffrey Lancet, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 11, 2017
Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome
Susmitha Apuri, Najla Al Ali, Eric Padron, et al.
Blood Advances
|
September 21, 2022
U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes
Rami Komrokji, Luis E Aguirre, Najla Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 14, 2016
Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome
Mintallah Haider, Najla Al Ali, Eric Padron, et al.
Blood Cancer Journal
|
November 15, 2022
Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
Andrew M Brunner, Alexander Gavralidis, Najla Al Ali, et al.
Blood
|
May 26, 2021
Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes
Rami Komrokji, Virginia Volpe, Onyee Chan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 23, 2015
Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome
Rami Komrokji, Hanadi Ramadan, Najla Al Ali, et al.
Haematologica
|
November 24, 2022
<i>IDH</i> mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy
Rami Komrokji, Najla Al Ali, Onyee Chan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 14, 2016
Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience
Joanna Grabska, Bijal Shah, Damon Reed, et al.
Page
of 9